Search research articles
Contact Us
Filters
Showing results (141-150 of 186) with videos related to
Page
of 19
Sort By:
Bulletin Du Cancer
|
April 12, 2026
[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]]
Frédéric Selle, Manuel Rodrigues, Benoît You, et al.
Bulletin Du Cancer
|
January 31, 2026
[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of high-grade ovarian epithelial cancer]
Frédéric Selle, Manuel Rodrigues, Benoît You, et al.
The American Journal of Pathology
|
April 4, 2012
Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway
David F Vincent, Johann Gout, Nicolas Chuvin, et al.
Acta Neuropathologica Communications
|
May 7, 2026
Ovarian central nervous system-type tumors: integrated neuropathological and methylation-based classification reveals site-related features
Martin Raby, Alexis Trécourt, Euphrasie Servant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
Cancer Research
|
July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression
Vanja Sisirak, Julien Faget, Michael Gobert, et al.
Cancer Research Communications
|
September 14, 2023
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
Boris Guyot, Flora Clément, Youenn Drouet, et al.
Plos Genetics
|
July 25, 2009
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas
David F Vincent, Kai-Ping Yan, Isabelle Treilleux, et al.
Science Translational Medicine
|
January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
Molecular Oncology
|
November 12, 2022
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group
Nour-El-Houda Mourksi, Cécile Dalban, Amélie Colombe-Vermorel, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 186) with videos related to
Sort By:
Page
of 19
Bulletin Du Cancer
|
April 12, 2026
[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]]
Frédéric Selle, Manuel Rodrigues, Benoît You, et al.
Bulletin Du Cancer
|
January 31, 2026
[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of high-grade ovarian epithelial cancer]
Frédéric Selle, Manuel Rodrigues, Benoît You, et al.
The American Journal of Pathology
|
April 4, 2012
Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway
David F Vincent, Johann Gout, Nicolas Chuvin, et al.
Acta Neuropathologica Communications
|
May 7, 2026
Ovarian central nervous system-type tumors: integrated neuropathological and methylation-based classification reveals site-related features
Martin Raby, Alexis Trécourt, Euphrasie Servant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
Cancer Research
|
July 28, 2012
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression
Vanja Sisirak, Julien Faget, Michael Gobert, et al.
Cancer Research Communications
|
September 14, 2023
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
Boris Guyot, Flora Clément, Youenn Drouet, et al.
Plos Genetics
|
July 25, 2009
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas
David F Vincent, Kai-Ping Yan, Isabelle Treilleux, et al.
Science Translational Medicine
|
January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
Molecular Oncology
|
November 12, 2022
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group
Nour-El-Houda Mourksi, Cécile Dalban, Amélie Colombe-Vermorel, et al.
Page
of 19